FINWIRES · TerminalLIVE
FINWIRES

Adveritas Says ARR Rises 8% in June Quarter To-Date

By

Adveritas (ASX:AV1) said its annualized recurring revenue (ARR) reached AU$16.3 million within the first two months of the June quarter, an increase of 8% from AU$15.08 million in around two months from March 31, according to a Tuesday Australian bourse filing.

The majority of new ARR added in the quarter to date has been derived from new US-based organizations outside of its established sports betting and online gaming segments, per the filing.

It said 652 sign-ups were registered with the TrafficGuard small and mid-sized enterprise self-serve platform to date since its launch on April 1, and 54 billable accounts were now active as paying subscribers. 120 advertisers were on active trial under the 30-day free trial period.

Its shares rose 2% in recent trading on Tuesday.

Related Articles

Asia

CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine

CanSino Biologics (HKG:6185, SHA:688185) initiated a phase 1/2 trial of its 24-valent pneumococcal conjugate vaccine, a broad-spectrum shot designed to prevent infections caused by 24 pneumococcal serotypes, according to a Tuesday filing with the Hong Kong bourse.The trial will evaluate the vaccine in subjects aged two months and older for the prevention of pneumococcal infections, which can cause diseases such as pneumonia and meningitis.The new product could expand coverage beyond the company's existing 13-valent pneumococcal vaccine, which was approved in China in June 2025.The firm said there were currently no 24-valent pneumococcal conjugate vaccines available on the global market.

$HKG:6185$SHA:688185
Asia

Viva Leisure Upgrades Fiscal 2026 Net Profit After Tax Guidance; Shares Gain 8%

Viva Leisure (ASX:VVA) raised its fiscal 2026 guidance for both statutory and underlying net profit after tax (NPAT), citing strong margin discipline and improving contribution from its technology, payments, licensing and retail division, according to a Tuesday filing with the Australian bourse.The company upgraded its statutory NPAT guidance to more than AU$12 million from a prior forecast of more than AU$11.5 million, and raised its underlying NPAT outlook to more than AU$17 million from over AU$16 million.Viva Leisure maintained its fiscal 2026 revenue guidance at greater than AU$237 million.The company's shares advanced more than 8% in recent Tuesday trade.

$ASX:VVA
Asia

China Medical System Gets China Trial Approval for Crohn's, Colitis Drug

China Medical System's (HKG:0867, SGX:8A8) said China's National Medical Products Administration approved clinical trials of its self-developed TYK2 inhibitor CMS-D001 for ulcerative colitis and Crohn's disease, according to a Tuesday Hong Kong bourse filing.The company said CMS-D001 is being developed for inflammatory bowel disease indications, including ulcerative colitis and Crohn's disease, and may also be developed for autoimmune conditions such as systemic lupus erythematosus in the future.

$HKG:0867$SGX:8A8